威高股份(01066.HK)中期纯利增44.2%至9.37亿元 中期息0.059元
格隆汇8月28日丨威高股份(01066.HK)公布,截至2019年6月30日止6个月,集团实现来自持续经营业务收入49.43亿元(人民币,单位下同), 同比增长19.1%; 公司拥有人应占溢利9.37亿元, 同比增44.2%; 基本每股盈利0.21元;拟派中期股息每股0.059元。
公告表示,不计特殊项目的公司拥有人应占纯利约为人民币9.37亿元,较上一年度同期增加约23.0%。同期特殊项目为收购爱琅医疗器械控股有限公司致存货评估增值,增加销售成约为人民币7570.7万元和收购爱琅一次性交易费用约为人民币3632.3万元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.